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ABSTRACT
Many epidemiological studies have assessed the genetic risk of having undiagnosed or of developing type 2 diabetes mellitus
(T2DM) using several single nucleotide polymorphisms (SNPs) based on ﬁndings of genome-wide association studies (GWAS).
However, the quantitative association of cumulative risk alleles (RAs) of such SNPs with T2DM risk has been unclear. The aim of
this meta-analysis is to review the strength of the association between cumulative RAs and T2DM risk. Systematic literature
searches were conducted for cross-sectional or longitudinal studies that examined odds ratios (ORs) for T2DM in relation to
genetic proﬁles. Logarithm of the estimated OR (log OR) of T2DM for 1 increment in RAs carried (1-ΔRA) in each study was
pooled using a random-eﬀects model. There were 46 eligible studies that included 74,880 cases among 249,365 participants. In 32
studies with a cross-sectional design, the pooled OR for T2DM morbidity for 1-ΔRA was 1.16 (95% conﬁdence interval [CI],
1.13–1.19). In 15 studies that had a longitudinal design, the OR for incident T2DM was 1.10 (95% CI, 1.08–1.13). There was large
heterogeneity in the magnitude of log OR (P < 0.001 for both cross-sectional studies and longitudinal studies). The top 10
commonly used genes signiﬁcantly explained the variance in the log OR (P = 0.04 for cross-sectional studies; P = 0.006 for
longitudinal studies). The current meta-analysis indicated that carrying 1-ΔRA in T2DM-associated SNPs was associated with a
modest risk of prevalent or incident T2DM, although the heterogeneity in the used genes among studies requires us to interpret the
results with caution.
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INTRODUCTION
Intensive lifestyle interventions (eg, promoting increased physical
activity and weight loss) can be eﬀective in decreasing the
incidence of type 2 diabetes mellitus (T2DM).1 However,
healthcare resources are limited, and participants in interventions
to prevent diabetes should be prioritized. Identiﬁcation of
individuals at high risk of T2DM could facilitate the targeting
of prevention eﬀorts to those who could beneﬁt from them and
reduce the cost of preventing T2DM.
Predicting T2DM in healthy individuals has been attempted
using a diabetes risk score that is derived from common clinical
information, such as adiposity, blood pressure, and family history
of T2DM. However, using the risk score is inevitably limited in
predicting T2DM because T2DM has a strong genetic basis;
concordance of T2DM is about 70% for monozygotic twins,
compared to about 20–30% for dizygotic twins.2
Limitations in predicting T2DM have driven researchers to
employ genetic risk assessments. Moreover, unlike clinical
markers, genetic markers do not change with time, so they
possess the advantage of identifying high-risk individuals long
before disease onset, which could enable early interventions for
preventing T2DM. Conventionally, family-based linkage studies
have played an important role in identifying genes having a large
eﬀect in monogenic disorders, such as maturity-onset diabetes
of the young.3 However, linkage studies have low power for
polygenic diseases that are inﬂuenced by multiple genes, as is
the case with the majority of those with T2DM. Therefore, using
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monogenic mutations would have very limited value for
predicting risk of disease in the general population because of
their low frequency.
Genome-wide association studies (GWAS) capture the great
majority of common genetic diﬀerences among individuals and
relate them to health and diseases.4 The GWAS potentially
represent a powerful new tool for identifying genes that inﬂuence
common diseases. Recently, GWAS identiﬁed an increasing
number of loci associated with susceptibility to T2DM. However,
each risk allele (RA) of single nucleotide polymorphisms (SNPs)
at these loci has a modest eﬀect size.5 Therefore, a combination of
several SNPs is required to substantially inﬂuence T2DM risk. A
genetic risk score potentially has the ability to predict disease risk
as a function of the combined eﬀects of SNPs. The most typical
approach to produce the genetic risk score is to count the total
number of RAs at each T2DM-associated SNP identiﬁed by
GWAS. Because the number of RAs carried is consequently a
quantiﬁable variable, it can be potentially used for clinical risk
assessment, similar to measurement of body mass index (BMI).
Recently, an increasing number of epidemiological studies have
investigated the eﬀect of cumulative RAs on T2DM risk.
However, the quantitative association between cumulative RAs
and T2DM risk has not been established, while the association of
BMI with T2DM risk was quantiﬁed using meta-analysis.6 The
aim of this meta-analysis is to comprehensively estimate the
strength of the association between cumulative RAs and T2DM
risk, including exploration of diﬀerences in the magnitude of
T2DM risk according to several study characteristics.
MATERIALS AND METHODS
Literature searches
Electronic literature search using EMBASE and MEDLINE (up
to 2015) was conducted for studies that quantiﬁed the genetic risk
of T2DM. This search was limited to articles published after the
International HapMap Project had identiﬁed a majority of the
common SNPs examined by GWAS in 2003.7 Manual searches
were added using the reference list of each included study.
Inclusion criteria
Study keywords were thesaurus terms related to genetic proﬁles
and T2DM (Table 1). Inclusion criteria were: 1) cross-sectional
design (for assessing the possibility of having undiagnosed
T2DM) or longitudinal design (for assessing the risk of
developing T2DM); 2) total number of RAs carried calculated
by summing the number of RAs in each SNP according to an
additive model (ie, 0, 1, and 2 were assigned for homozygosity
for a non-RA, heterozygosity for an RA, and homozygosity for an
RA, respectively) were analyzed as an exposure; 3) two or more
SNPs were combined for assessing genetic risk; and 4) the odds
ratio (OR) for each increment in the number of RAs carried (1-
ΔRA) and its corresponding standard error (SE) (SE is usually
provided for the natural logarithm of OR [log OR] rather than for
the OR) were presented or could be estimated. Exceptionally,
studies that used the dominant model (ie, counting 1 for
homozygosity or heterozygosity for having an RA and 0 for
having no RA) were also considered.
Haplotypes into which alignments of multiple SNPs were
classiﬁed were regarded as one unit because these SNPs could
not be separated into individual SNPs. Therefore, studies that
examined the association between several haplotypes and T2DM
risk were excluded, even if two or more SNPs were used. Due
to the necessity of maintaining homogeneity across studies as
closely as possible, the OR needed to be adjusted for at least two
of the following three covariates: age, gender, and BMI. For the
same reason, studies were excluded if they examined T2DM risk
in relation to a weighted risk score that was produced by
summing the number of RAs multiplied by the SNP-speciﬁc
eﬀect size. In longitudinal studies, if the risk measure was
expressed as a relative risk (RR) rather than OR, we included
such studies on the condition that the incidence rate in the study
population was reported. In that case, the RR was converted into
an OR using the following formula: OR ¼ RRð1PoÞ
1PoRR , in which the
incidence rate was imputed to Po.8 Also, as the SE corresponding
to the natural logarithm of RR (log RR) was converted into the
SE corresponding to log OR, the Miettinen test-based approach
was applied: SEðlogORÞ ¼ SEðlogRRÞ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
logOR
logRR
q
.9
Data extraction
For each included study, two authors (S.K. and H.So.) extracted
the following information relevant to study characteristics:
country, ethnic group (if information was presented), design
(cross-sectional or longitudinal), observational periods (in case
of a longitudinal study), number of participants and cases, mean
age, proportion of men and women, mean BMI, study-speciﬁc
covariates, criteria of T2DM cases and non-cases, and used SNPs.
Inconsistencies were resolved via discussion. Study quality was
assessed by 10 basic questions that should be answered in the
aﬃrmative to indicate a reliable report (Table 2).4 One point was
awarded to a study for each “Yes” answer, with a maximum score
of 10.
If a study presented several ORs for T2DM with diﬀerent
levels of adjustment, the most completely adjusted OR was
chosen. If a study presented several ORs with diﬀerent
combinations of SNPs used for T2DM screening, the OR that
had the greatest eﬀect size was chosen. In addition, if a study
Table 1. Study keywords for this meta-analysis
Using EMBASE
Terms related to thesaurus
#1 [related to genetic backgrounds]
“genetic variability” OR “genetic polymorphism” OR “single nucleotide
polymorphism [Exp]” OR “genetic association” OR “genotyping” OR “genetic
susceptibility” OR “genetic resistance” OR “genetic predisposition”
#2 [related to type 2 diabetes mellitus]
“non insulin dependent diabetes mellitus – epidemiology” OR “diabetes mellitus –
epidemiology”
#3 #1 AND #2
Using MEDLINE
#4 [related to genetic backgrounds]
“Genome-Wide Association Study” OR “Genetic Association Studies” OR
“Polymorphism, Single Nucleotide” OR “Genetic Variation [Exp]” OR
“Polymorphism, Genetic [Exp]” OR “Genotype” OR “Genetic Predisposition to
Disease”
#5 [related to type 2 diabetes mellitus]
“Diabetes Mellitus, Type 2 – epidemiology” OR “Diabetes Mellitus, Type 2 –
genetics” OR “Diabetes Mellitus – genetics” OR “Diabetes Mellitus –
epidemiology”
#6 #4 AND #5
Combination of EMBASE and MEDLINE
#7 #3 OR #6
[Exp] indicates automatic inclusion of all the narrower terms under the
speciﬁed descriptor in the thesaurus hierarchy.
Using the connector “–” limits a descriptor term to a Subheading appearing
after the connector.
Cumulative Risk Alleles and Type 2 Diabetes Mellitus
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Table 2. Assessment of study quality using 10 basic questions about genome-wide association studies
First author Year
Quality
Score
Q.1 Q.2 Q.3 Q.4 Q.5 Q.6 Q.7 Q.8 Q.9 Q.10
Oian18 2015 8 Yes Yes Yes Yes Yes Yes No Yes Yes No
Talmud17 2015 6 Yes Yes No Yes Yes Yes Yes No No No
Chen21 2014 5 No No Yes Yes Yes Yes Yes No No No
Langenberg20 2014 5 No Yes No Yes Yes Yes Yes No No No
Villegas19 2014 3 No No No No Yes Yes Yes No No No
Anand26 2013 3 No Yes No Yes No Yes No No No No
Kalnina27 2013 5 Yes No No Yes Yes No Yes No No Yes
Imamura25 2013 5 Yes No Yes Yes Yes Yes No No No No
Peters28 2013 4 No No No No Yes Yes Yes No No Yes
Ramya24 2013 4 Yes No No No Yes Yes Yes No No Yes
Robiou-du-Pont23 2013 5 Yes No Yes Yes No Yes Yes No No No
Tam22 2013 4 Yes No Yes Yes No Yes No No No No
Cauchi29 2012 3 Yes No No Yes No Yes No No No No
Cooke30 2012 5 Yes No Yes Yes Yes Yes No No No No
Gamboa-Meiendez31 2012 3 Yes No No Yes No Yes No No No No
Iwata32 2012 8 Yes No Yes Yes Yes Yes Yes Yes Yes No
Long33 2012 5 Yes No Yes Yes Yes Yes No No No No
Vassy34 2012 3 Yes Yes No No No Yes No No No No
Vassy35 2012 3 Yes Yes No No Yes No No No No No
Villegas36 2012 5 Yes No Yes Yes Yes Yes No No No No
Yamakawa-Kobayashi37 2012 3 Yes No No Yes No Yes No No No No
Li38 2011 3 No Yes No Yes No Yes No No No No
Martinez-Gomez39 2011 6 Yes No No Yes Yes No Yes Yes Yes No
Rees40 2011 4 Yes No Yes Yes No Yes No No No No
Tabara41 2011 3 Yes Yes No No No Yes No No No No
Uusitupa42 2011 4 Yes Yes No Yes No Yes No No No No
Fontaine-Bisson43 2010 4 Yes No No Yes No Yes No No No Yes
Qi44 2010 3 Yes No No Yes No Yes No No No No
Rotger45 2010 1 No No No No No Yes No No No No
Wang46 2010 3 Yes No No Yes No Yes No No No No
Waters47 2010 2 No No Yes No No Yes No No No No
Xu48 2010 7 Yes Yes Yes Yes Yes Yes Yes No No No
Cornelis49 2009 5 No Yes Yes Yes Yes Yes No No No No
Hu50 2009 6 Yes No Yes Yes Yes Yes Yes No No No
Lin51 2009 3 Yes No No Yes No Yes No No No No
Miyake52 2009 6 No No Yes No Yes Yes Yes Yes Yes No
Nordman53 2009 3 Yes No No Yes No Yes No No No No
Rong54 2009 2 Yes No No No No Yes No No No No
Schulze55 2009 2 No No No Yes No Yes No No No No
Cauchi56 2008 7 Yes No Yes Yes Yes Yes Yes Yes No No
Lyssenko57 2008 7 Yes No Yes Yes Yes Yes No Yes Yes No
Meigs58 2008 4 Yes No No Yes Yes Yes No No No No
Vaxillaire59 2008 5 Yes No No Yes Yes Yes Yes No No No
Scott60 2006 4 Yes No No Yes Yes Yes No No No No
Hansen61 2005 5 Yes No No Yes Yes Yes No No No Yes
Zacharova62 2005 4 Yes Yes No No No Yes No No No Yes
Each question used for assessment of study quality is given below.4 If the answer is “Yes” to a question, a study could be awarded 1 point. Full score is 10.
Q.1. Are the cases deﬁned clearly and reliably so that they can be compared with patients typically seen in clinical practice?
Q.2. Are case and control participants demonstrated to be comparable to each other for important characteristics that might also be related to genetic variation and
to the disease? In longitudinal studies, the answer was considered to be “Yes” if the diabetes risk was adjusted for age, gender, and obesity index.
Q.3. Was the study of suﬃcient size to detect modest odds ratios or relative risks (1.3–1.5)?
(At least 1,500 cases are needed to obtain 90% statistical power for detecting a 30% allelle with a 1.5 odds ratio at P < 10−8 of a signiﬁcant level.+)
Q.4. Was the genotyping platform of suﬃcient density to capture a large proportion of the variation in the population studied?
Q.5. Were appropriate quality control measures applied to genotyping assays, including visual inspection of cluster plots and replication on an independent
genotyping platform?
(The concordance rate needed to be presented by using a duplicate sample if the study met this criterion.)
Q.6. Did the study reliably detect associations with previously reported and replicated variants (known positives)?
Q.7. Were stringent corrections applied for the many thousands of statistical tests performed in deﬁning the P value for signiﬁcant associations?
Q.8. Were the results replicated in independent population samples?
Q.9. Were the replication samples comparable in geographic origin and phenotype deﬁnition, and if not, did the diﬀerences extend the applicability of the
ﬁndings?
Q.10. Was evidence provided for a functional role for the gene polymorphism identiﬁed?
+Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008;322:881–8.
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performed both overall and subgroup analyses, we chose the data
based on subgroup analyses if characteristics, such as mean age,
proportion of men, and mean BMI, in each subgroup were
described; otherwise, data based on an overall analysis were
chosen.
Data synthesis
Most of the included studies did not directly present data on the
OR for the increment in the number of RAs carried. To estimate
the OR, the log ORs in several genetic risk groups in the
individual study were regressed to their corresponding mean
number of RAs carried.10 If data on the mean number of RAs
carried could not be directly extracted, the midpoint value of the
upper and lower boundaries of the number of RAs carried was
used for intermediate categories. In other categories (ie, highest or
lowest category), we assumed that the frequency distribution of
the number of RAs carried was normal and regressed the number
of RAs carried to its corresponding Z-value for the rank percentile
in the upper and lower boundary in each intermediate category
and extrapolated the regression line into the highest and lowest
categories. This regression is called generalized least squares for
trend estimation (GLST), for which a program was developed by
Orsini et al.11 This program can calculate a weighted linear
regression of log OR across categories of the number of RAs
carried with consideration of the covariance among the log ORs
as long as data on the total number of participants and cases are
provided.
Cross-sectional studies and longitudinal studies were analyzed
separately. In each study, the OR of T2DM for 1-ΔRA was
transformed into log OR because its corresponding SE is
provided for log OR rather than for the OR. The log OR was
pooled with a random-eﬀects model12 followed by exponentiation
of the pooled log OR to obtain the OR of interest. Study
heterogeneity was assessed by Q-statistics or I-squared overall
and within each strata after stratiﬁcation.13
Publication bias was assessed by two formal statistical tests:
Begg’s rank correlation test14 and Egger’s regression asymmetry
test.15 For statistically suspected publication bias, the trim and ﬁll
method was adopted to adjust the pooled T2DM risk, assuming
that the asymmetry of the funnel plot is entirely due to publication
bias. This method includes detection of unpublished studies that
distorted the funnel plot, ﬁlling the results of these hypothetical
studies to recover the symmetry of the funnel plot, and
recalculation of the pooled eﬀect size as if these studies had
actually existed.16
Sensitivity analysis
The pooled OR was estimated for subgroups after stratiﬁcation on
the basis of the following pre-speciﬁed study characteristics:
number of SNPs (<10 or ≥10), mean age (<55 years or ≥55
years in cross-sectional studies; <50 years or ≥50 years in
longitudinal studies), proportion of men (<50% or ≥50%),
country where the study was conducted (Western or non-
Western), ethnic group (Asian or non-Asian), mean BMI
(<27 kg=m2 or ≥27 kg=m2 in cross-sectional studies; <25 kg=m2
or ≥25 kg=m2 in longitudinal studies), whether the OR was or
was not adjusted for BMI, whether the oral glucose tolerance test
(OGTT) was thoroughly performed for detecting any cases of
T2DM, and whether subjects with impaired glucose tolerance
(IGT) or impaired fasting glucose (IFG) were excluded from non-
T2DM cases. The cut-oﬀ values for mean age and BMI used in
the stratiﬁed analyses corresponded to these median values in
cross-sectional and longitudinal studies (median age: 55.7 years
for cross-sectional studies and 50.6 years for longitudinal studies;
median BMI: 26.7 kg=m2 for cross-sectional studies and 25.9
kg=m2 for longitudinal studies). Univariate log-linear meta-
regression analysis was used to test the diﬀerences in the
magnitude of the OR between strata.
Multivariate log-linear meta-regression analyses were added
using several study characteristics simultaneously as explanatory
variables. In these regression analyses, log OR of T2DM for
1-ΔRA was used as an objective variable. The T2DM-susceptible
genes that were used in each study were inconsistent. Therefore,
we added a meta-regression analysis of whether or not each of
these genes was examined. This analysis was limited to the top 10
of the commonly used genes in this meta-analysis in order to
maintain statistical power. All analyses were based on statistical
software STATA version 14 (STATA Corp., College Station, TX,
USA). The meta-regression analyses were performed by installing
the “metareg” command into STATA. We also installed the “glst”
command to estimate the OR for carrying 1-ΔRA using GLST.
RESULTS
Eligible studies
Figure 1 is a ﬂow chart showing the procedure for identifying
studies that met the initial inclusion criteria. Of 7,381 studies
retrieved through the electronic literature search, 96 investigated
the genetic risk for T2DM combining two or more SNPs. After
10 studies in which the study population overlapped with other
studies were eliminated, there remained 86 studies for further
review. Forty studies did not allow estimation of the adjusted
OR for T2DM for one increment in risk alleles carried. Finally,
46 original studies17–62 in which the OR for T2DM for 1-ΔRA
was presented or could be estimated, including 75,651 cases
among 249,365 participants, were eligible. Twenty-eight
studies17,19,20,23,26,27,29,30,33–35,38,40,42,43,45–47,49,51,53,55–60,62 analyzed
T2DM risk in Western countries. Table 3 shows characteristics
of the 46 eligible studies. Most studies were not considered to
have targeted exclusively a single ethnicity, and only 5
studies19,26,39,47,57 performed analyses by ethnicity. Only 2
studies49,62 analyzed men and women separately, and all but 3
studies37,46,53 included both genders. One study48 analyzed T2DM
risk from both cross-sectional and longitudinal perspectives.
Table 4 summarizes the criteria for T2DM cases and
non-cases in each study. OGTT was used for any participant
in whom T2DM was undiagnosed using other methods
in 20 studies.22,24,26,30,37,40,43,45,46,48–50,53,54,57,58,60–63 Among
cross-sectional studies, 7 studies24,48,50,53,54,60,61 and 13
studies18,29,31,33,36,37,44,48,50,53,56,60,64 excluded participants with
IGT and IFG, respectively, from non-T2DM cases. Table 5
shows details of covariates that each study arbitrarily considered.
Study-speciﬁc covariates were heterogeneous among studies.
However, T2DM risk was adjusted for BMI in most studies (37
studies).17–20,22–28,31–38,40–42,44–56,59,62
Table 2 describes the assessment of study quality. No study
received a full score of 10. Also, there were some “no” responses
to each of the items. Mean (standard deviation) score was 4.3
(1.6). Table 6 summarizes the T2DM-associated loci used in each
study. The number of SNPs ranged from 2 to 65 (median, 14.0
SNPs). Table 7 indicates the rank of the genes that were
commonly used in association with prevalent or incident
Cumulative Risk Alleles and Type 2 Diabetes Mellitus
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T2DM. The top 10 genes were CDKAL1, TCF7L2, CDKN,
HHEX, IGFBP2, SLC30A8, KCNJ11, PPARG, FTO, and
KCNQ1. Total number of SNPs that were covered by at least
one of the included studies was 116.
Cross-sectional studies
Among the 46 included studies, 32 stud-
ies18,19,21–25,27–33,36,37,39,40,43–48,50–54,56,60,61 that included 145,162
participants and 57,985 cases used a cross-sectional design.
Mean age and BMI ranged from 33.7–68.8 years and from
23.2–36.9 kg=m2, respectively. The median proportion of men
was 47%. Figure 2 shows a forest plot of ORs for T2DM, with a
95% conﬁdence interval (CI), for 1-ΔRA. Overall, the OR for
T2DM was highly signiﬁcant (OR 1.16; 95% CI, 1.13–1.19;
P < 0.001). However, there was highly signiﬁcant between-study
heterogeneity in the magnitude of ORs for T2DM (I-squared =
93.6%, P < 0.001). Publication bias was statistically suggested
using both Begg’s and Egger’s tests (P = 0.03 and P = 0.01,
respectively). Adjustment for publication bias using the trim and
ﬁll method slightly attenuated the T2DM risk but it remained
highly signiﬁcant (OR 1.15; 95% CI, 1.12–1.18; P < 0.001).
Table 8 shows the results of the stratiﬁed analysis of T2DM
risk for 1-ΔRA using several pre-speciﬁed study characteristics.
The OR for 1-ΔRA was consistently signiﬁcant throughout any
strata within individual subheadings. However, studies using 10
or more SNPs for T2DM screening revealed a smaller OR than
those using less than 10 SNPs (pooled OR 1.14; 95% CI, 1.11–
1.17 vs OR 1.25; 95% CI, 1.19–1.31; P = 0.002). The strength of
the association was not signiﬁcantly inﬂuenced by whether the
OR was adjusted for BMI (P = 0.82). A signiﬁcantly stronger
association with T2DM risk was observed in studies of
participants having a relatively lower mean BMI (<27 kg=m2 vs
≥27 kg=m2; P = 0.03) while a signiﬁcantly weaker association
was observed in studies that were women-dominant (P = 0.04).
A negative association between mean BMI and T2DM risk for
1-ΔRA was also observed by entering the mean BMI as a
continuous variable, predicting ORs of 1.18 and 1.11 for mean
BMIs of 30 kg=m2 and 25 kg=m2, respectively. The pooling of
studies that were considered to primarily represent Asian
ethnicity, which were conducted in Japan, China, India,
Singapore, or Pakistan, or targeted for Japanese-Americans,
resulted in a signiﬁcantly larger OR than the pooling of the other
studies (P = 0.01). Also, excluding studies conducted in Western
countries, including the United States, Mexico, Latvia, the United
Kingdom, Sweden, Switzerland, France, Canada, or Denmark,
resulted in a smaller OR compared with studies conducted
in those Western countries (P = 0.02). Studies that excluded
individuals with IGT from the non-T2DM cases revealed a
larger OR compared with studies that did not (P = 0.002), while
studies that excluded individuals with IFG did not inﬂuence the
magnitude of the OR. Analysis was not inﬂuenced by whether or
not OGTT was used for T2DM screening (P = 0.17).
7,381 citations were found in databases 
using search terms from 
MEDLINE or EMBASE
6,839 Articles were excluded based on title and 
abstract
542 articles were left for further review
134 studies were not relevant to our topic of 
interest
75 were not original articles
37 did not consider type 2 diabetes mellitus as 
an independent study outcome
22 did not examine genes related to type 2 
diabetes mellitus or consider genetic risk as an 
explanatory variable 
96 articles were left for full-paper review
315 studies did not meet initial inclusion criteria
13 were case studies
276 did not combine two or more genes in 
assessing genetic risk
12  lacked data required to calculate number 
of risk alleles carried
13 lacked data required to estimate risk 
measure and its corresponding standard 
error
1 investigated genes that were not associated 
with type 2 diabetes mellitus 3 studies were obtained by manual searches of 
reference lists
40 could not allow estimation of adjusted or 
for type 2 diabetes mellitus for 1 
increment in risk alleles carried
46 articles met inclusion criteria
86 articles were left for further review
10 had study population that overlapped with 
other studies presenting more detailed 
information
Figure 1. Flowchart of search for eligible studies
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Table 9 shows the results of the multivariate meta-regression
analysis that simultaneously entered several of the study
characteristics used in the stratiﬁed analyses as explanatory
variables. Consistent with the results of the stratiﬁed analyses that
were previously described (ie, univariate analyses), studies that
had a women-dominant population and were examined in Western
countries revealed a smaller OR for T2DM for 1-ΔRA (P = 0.005
and P = 0.02, respectively) while studies that primarily targeted
those of Asian ethnicity revealed a larger OR (P = 0.02). Unlike
the results of the univariate analysis, neither the mean BMI,
country where the individual study was conducted (Western
or non-Western), nor the ethnic group (Asian or non-Asian)
inﬂuenced the magnitude of the OR. However, in the multivariate
analysis, the inﬂuence of the mean BMI became non-signiﬁcant.
Table 10 shows the results of univariate and multivariate meta-
regression analyses according to whether each of the top 10
Table 3. Characteristics of each eligible study analyzed in this meta-analysis
First author Year Country Design
Follow-up
durationa
(years)
Subgroup
Number of
participants
Number of
cases
Mean age % men BMI
Oian18 2015 China C 6,063 2,853 57.3 37.5% 23.5
Talmud17 2015 UK L 10 13,294 804 N=A 59.5% N=A
Chen21 2014 Singapore C 4,677 2,338 55.2 47.1% 23.6
Langenberg20 2014 UK L 8.9 18,890 8,245 52.3 38.0% 26.7
Villegas19 2014 USA C Non-Hispanic Whites 6,377 545 52.8 45.0% 27.4
Non-Hispanic Blacks 3,054 337 43.7 44.0% 28.9
Mexican Americans 3,621 455 43.6 49.0% 28.2
Anand26 2013 Canada L 3.3 European 5,449 586 55.0 39.2% 30.4
South African 2,268 194 44.9 51.6% 26.4
Latinos 2,815 218 52.6 33.2% 30.8
Imamura25 2013 Japan C 4,399 2,613 58.1 45.2% 23.8
Kalnina27 2013 Latvia C 2,047 981 56.7 32.1% 29.7
Peters28 2013 Australia C 3,322 967 55.7 47.4% 26.9
Ramya24 2013 India C 1,957 940 45.8 44.3% 24.3
Robiou-du-Pont23 2013 France C 5,162 2,077 54.5 43.5% 26.7
Tam22 2013 China C 8,451 5,882 52.2 46.1% 24.1
Cauchi29 2012 France C 2,248 1,193 56.1 32.5% 28.1
Cooke30 2012 USA C 4,045 2,652 55.7 41.9% 30.9
Gamboa-Meiendez31 2012 Mexico C 2,017 1,027 53.5 37.6% 28.6
Iwata32 2012 Japan C Other than Tokyo University 1,487 724 68.8 54.5% 23.6
Tokyo University 2,041 1,182 67.1 53.2% 24.0
Long33 2012 USA C 4,288 1,554 56.8 30.7% 31.5
Vassy34 2012 USA L 23.9 2,439 215 25.1 44.0% 24.3
Vassy35 2012 USA L 26.9 1,030 90 14.4 44.7% 20.7
Villegas36 2012 China C 6,001 2,679 55.6 23.8% 26.4
Yamakawa-Kobayashi37 2012 Japan C 750 333 54.0 100% 23.9
Li38 2011 UK L 12.9 21,157 729 58.9 49.8% 26.5
Martinez-Gomez39 2011 Mexico C Guerrero 400 200 50.7 36.0% 28.2
Mexico 1,065 546 48.6 50.5% 28.4
Rees40 2011 UK C 3,262 1,659 55.8 49.4% 26.3
Tabara41 2011 Japan L 9.4 1,824 95 62.0 54.4% 23.5
Uusitupa42 2011 Finland L 6.2 522 185 55.4 32.8% 31.2
Fontaine-Bisson43 2010 Sweden C 2,751 1,327 53.3 54.2% 27.6
Qi44 2010 China C 2,332 424 58.8 42.8% 24.2
Rotger45 2010 Swiss C 644 94 39.9 79.5% 23.2
Wang46 2010 Finland C 7,232 518 57.7 100% 27.0
Waters47 2010 USA C African-Americans 2,546 1,077 60.2 40.9% 28.6
Native Hawaiians 1,559 576 55.6 48.2% 28.7
European-Americans 1,539 533 57.6 51.5% 26.6
Latinos 4,404 2,220 59.3 48.0% 27.7
Japanese 3,497 1,736 59.2 56.2% 25.2
Xu48 2010 China C 5,512 1,825 61.1 40.9% 25.2
L 3.5 734 67 60.0 39.0% 24.8
Cornelis49 2009 USA L 10 6,310 2,809 48.5 40.2% 25.9
Hu50 2009 China C 3,634 1,849 59.3 46.9% 23.8
Lin51 2009 USA C 5,360 356 53.3 47.4% 25.8
Miyake52 2009 Japan C 4,678 2,316 64.4 52.1% 23.5
Nordman53 2009 Sweden C 771 243 52.3 100% 29.5
Rong54 2009 Iadia C 2,745 1,161 33.7 N=A 36.9
Schulze55 2009 Germany L 7 2,541 579 50.6 51.1% 26.9
Cauchi56 2008 France C 8,827 4,232 58.6 41.9% 26.7
Lyssenko57 2008 Sweden L 23.5 Malmo 16,061 2,063 45.5 51.7% 24.3
Botnia 2,770 138 44.9 64.9% 25.6
Meigs58 2008 USA L 28 2,434 255 35.0 45.5% 24.9
Vaxillaire59 2008 France L 9 3,442 292 47.7 46.8% 24.3
Scott60 2006 USA C 2,104 1,151 64.2 44.3% 28.4
Hansen61 2005 Denmark C 5,897 1,164 48.4 55.8% 26.3
Zacharova62 2005 Finland L 3.3 223 102 54.7 49.5% 30.9++
BMI, body mass index; C, cross-sectional; L, longitudinal.
aIn study using longitudinal design.
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previously mentioned genes were used or not. In both univariate
and multivariate analyses, the FTO gene was associated with a
lower OR for T2DM. In the multivariate analysis, the 10 genes
explained 59.9% of the variance in the log OR (P = 0.04).
Longitudinal studies
Included were 15 longitudinal studies17,20,26,34,35,38,41,42,48,49,55,57–59,62
comprised of 104,203 participants, among which 17,666
participants developed T2DM. Figure 3 shows a forest plot of
ORs of T2DM with 95% CI of T2DM for 1-ΔRA. The pooled
OR for 1-ΔRA was 1.10 (95% CI, 1.08–1.13), which was
signiﬁcantly smaller than when cross-sectional studies were
pooled (P = 0.04). Publication bias was detected using Egger’s
test (P = 0.04) but not using Begg’s test (P = 0.40). However,
the adjustment for publication bias resulted in no change in the
overall estimate.
Two studies26,62 targeted exclusively IGT participants, while
the other studies did not specify participants at high risk of T2DM
according to IGT values. However, after excluding those studies,
the overall OR was not inﬂuenced (OR 1.11; 95% CI, 1.08–1.14;
P = 0.70). In the results of stratiﬁed and multivariate meta-
regression analyses using several study characteristics, no
variables that inﬂuenced T2DM risk could be detected, partly
because these sensitivity analyses had insuﬃcient statistical
power due to the small number of datasets (Table 11 and
Table 12). Nevertheless, studies using ≥10 SNPs revealed a
smaller OR than those using <10 SNPs in the stratiﬁed analysis
(pooled OR 1.10; 95% CI, 1.07–1.12 vs OR 1.34; 95% CI,
1.21–1.49; P = 0.005) (Table 11). Studies using 10 or more
SNPs for T2DM screening revealed smaller ORs than those using
less than 10 SNPs. Table 13 shows results of univariate and
multivariate meta-regression analyses indicating whether each of
the top commonly used genes was used for prediction of T2DM.
Although none of the 10 genes signiﬁcantly inﬂuenced the log
OR of T2DM risk in both univariate and multivariate meta-
regression analyses, multivariate analysis indicated that 67.5% of
the variance in the log OR could be explained by whether or not
each of the 10 genes was used (P = 0.006).
Table 4. Criteria for cases and non-cases in each included study
First author Design
Criteria
Cases Non-cases
Oian18 C FPG ≥ 7.0mmol=l FPG < 5.6mmol=l
Talmud17 L self-report or FPG ≥ 7.0mmol=l FPG < 7.0mmol=l
Chen21 C interview or A1C > 6.0% A1C ≤ 6.0%
Langenberg20 L self-report, registry, medical record unclear
Villegas19 C questionnaire questionnaire
Anand26 L FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l IFG or IGT
Kalnina27 C FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 7.0mmol=l, 2hPG < 11.1mmol=l
Imamura25 C registry registry
Peters28 C unclear unclear
Ramya24 C 2hPG ≥ 11.1mmol=l 2hPG < 7.8mmol=l
Robiou-du-Pont23 C FPG ≥ 7.0mmol=l FPG < 7.0mmol=l
Tam22 C FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l unclear
Cauchi29 C FPG ≥ 7.0mmol=l FPG < 5.6mmol=l
Cooke30 C FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 7.0mmol=l, 2hPG < 11.1mmol=l
Gamboa-Meiendez31 C casual PG ≥ 11.1mmol=l or FPG ≥ 7.0mmol=l FPG < 5.6mmol=l, no FH of DM
Iwata32 C unclear A1C < 6.0%
Long33 C casual PG ≥ 11.1mmol=l or A1C ≥ 6.5% FPG < 6.1mmol=l, A1C < 6.0%
Vassy34 L FPG ≥ 7.0mmol=l FPG < 7.0mmol=l
Vassy35 L FPG ≥ 7.0mmol=l FPG < 7.0mmol=l
Villegas36 C FPG ≥ 7.0mmol=l FPG < 5.6mmol=l, A1C < 6.1%
Yamakawa-Kobayashi37 C FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 5.6mmol=l, A1C < 5.8%
Li38 L FPG ≥ 7.0mmol=l FPG < 7.0mol=l
Martinez-Gomez39 C FPG ≥ 7.0mmol=l FPG < 7.0mol=l
Rees40 C FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 5.6mmol=l or (FPG < 6.1mmol=l, 2hPG < 7.8mmol=l) or casual PG < 6.7mmol=l
Tabara41 L FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 7.0mmol=l, 2hPG < 11.1mmol=l
Uusitupa42 L FPG ≥ 7.8mmol=l or 2hPG ≥ 11.1mmol=l FPG < 7.8mmol=l, 2hPG < 11.1mmol=l
Fontaine-Bisson43 C FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 7.0mmol=l, 2hPG < 11.1mmol=l
Qi44 C FPG ≥ 7.0mmol=l FPG < 5.6mmol=l
Rotger45 C casual PG ≥ 11.1mmol=l or FPG ≥ 7.0mmol=l casual PG < 11.1mmol=l, FPG < 7.0mmol=l
Wang46 C FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 7.0mmol=l, 2hPG < 11.1mmol=l
Waters47 C unclear unclear
Xu48 C FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 6.1mmol=l, 2hPG < 7.8mmol=l
L FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 7.0mmol=l, 2hPG < 11.1mmol=l
Cornelis49 L FPG ≥ 7.8mmol=l or 2hPG ≥ 11.1mmol=l FPG < 7.8mmol=l, 2hPG < 11.1mmol=l
Hu50 C FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 6.1mmol=l, 2hPG < 7.8mmol=l
Lin51 C FPG ≥ 7.0mmol=l FPG < 7.0mmol=l
Miyake52 C physician diagnosis for Japanese, registry for Chinese A1C < 5.6% for Japanese, FPG < 6.1mmol=l for Chinese
Nordman53 C FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 6.1mmol=l, 2hPG < 7.8mmol=l
Rong54 C FPG ≥ 7.8mmol=l or 2hPG ≥ 11.1mmol=l FPG < 7.8mmol=l, 2hPG < 11.1mmol=l
Schulze55 L questionnaire questionnaire
Cauchi56 C casual PG ≥ 11.1mmol=l or FPG ≥ 7.8mmol=l FPG < 6.1mmol=l, no FH of DM
Lyssenko57 L FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 7.0mmol=l, 2hPG < 11.1mmol=l
Meigs58 L FPG ≥ 7.8mmol=l or 2hPG ≥ 11.1mmol=l FPG < 7.0mmol=l, 2hPG < 11.1mmol=l
Vaxillaire59 L FPG ≥ 7.0mmol=l FPG < 7.0mmol=l
Scott60 C FPG ≥ 7.8mmol=l or 2hPG ≥ 11.1mmol=l FPG < 6.1mmol=l, 2hPG < 7.8mmol=l
Hansen61 C FPG ≥ 7.0mmol=l or 2hPG ≥ 11.1mmol=l FPG < 6.1mmol=l, 2hPG < 7.8mmol=l
Zacharova62 L FPG ≥ 7.8mmol=l or 2hPG ≥ 11.1mmol=l 7.8mmol=l = < 2hPG < 11.1mmol=l, FPG < 7.8mmol=l
2hPG, 2-hour post glucose concentration; A1C, hemoglobin A1C; ADA, American Diabetes Association criteria for diabetes; FH of DM, family history of
diabetes mellitus; FPG, fasting plasma glucose; IFG, impaired fasting glucose; IGT, impaired glucose tolerance.
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DISCUSSION
The current meta-analysis indicated that 1-ΔRA in T2DM-
associated SNPs was associated with a modest risk of prevalent
or incident T2DM. A previous meta-analysis6 indicated that the
pooled RR of incident T2DM was 1.87 for an increment of
4.3 kg=m2 in the BMI. If the magnitude of T2DM risk is
compared between 1-ΔRA and 1-ΔBMI, 1-ΔRA corresponds
to only 0.58-ΔBMI (Δ1.7 kg, if body height is 1.7 meters),
assuming that the cumulative incidence rate of T2DM in the
referent is p0 = 10% and the OR is transformed into an RR using
the following formula: RR ¼ ORð1p0Þþp0OR.
8 This estimation was
made by the following calculations:
1:10
ð1  0:1Þ þ 0:1  1:10 ¼ 1:089
logð1:089Þ ¼ 0:085
logð1:87Þ
4:3
¼ 0:146
0:085
0:146
¼ 0:58
In other words, having 1 RA was equivalent to losing less than
2 kg body weight.
Assuming the monotonicity between the number of RAs
carried and T2DM risk, the magnitude of disease risk will
endlessly expand with increases in the RAs carried, even if the
eﬀect size of each SNP is modest. Therefore, GWAS may be able
to detect individuals at extremely high risk of T2DM if the
number of the identiﬁed T2DM-associated SNPs is progressively
increased. However, the magnitude of T2DM risk might reach
a plateau, which was suggested from the result of the stratiﬁed
analysis that indicated that studies using a larger number of
SNPs (10 or more) revealed a smaller OR of T2DM for 1-ΔRA
compared with those using a smaller number of SNPs. Although
the observed higher risk when using a smaller number of genes
could be spurious due to the winner’s curse eﬀect (eg, T2DM risk
would be higher when using only the top two genes that were
strongly associated with susceptibility to T2DM than when using
the top 10 genes), this result reﬂects the fact that the T2DM-
susceptible loci were detected in order of descending eﬀect
size related to T2DM risk among all proposed loci.65 Of note,
although the magnitude of genetic T2DM risk was modest, this
did not mean that the risk was ignorable from the result of the
stratiﬁed analysis that indicated that the association of cumulative
RAs with T2DM risk was not weakened after adjusting the
T2DM risk for BMI. This result suggested that the genetic T2DM
risk existed independently of obesity, which is well known as one
of the greatest risk factors for T2DM.
The current meta-analysis indicated a large heterogeneity in the
magnitude of the T2DM risk for cumulative RAs, which was in
a large part explained by the choice of the T2DM-susceptible
genes. This suggested that the magnitude of T2DM risk depended
on what genes were used. In particular, the cross-sectional studies
that used the FTO gene revealed a lower OR compared with those
that did not use it, which suggested that it is unnecessary to
examine the FTO gene if clinical risk factors for T2DM were
simultaneously assessed. FTO is one of the most well-known
of the obesity-associated genes.66 Considering that the OR for
T2DM was adjusted for obesity in most of the studies included
in this meta-analysis, the T2DM risk associated with the FTO
gene could have been masked by that associated with obesity.
Although the magnitude of T2DM risk was not inﬂuenced by
whether or not FTO was used in the longitudinal studies, the
inconsistency in the results between the meta-analysis of cross-
sectional studies and that of longitudinal studies could be
explained by diﬀerences in the exposure to risk factors (ie,
participants in longitudinal studies were recruited before they
became obese, although those in cross-sectional studies had
already become obese at recruitment). Despite the heterogeneity
in the choice of the T2DM-susceptible genes, the forest plots
shown in Figure 2 and Figure 3 indicate that the OR for carrying
1-ΔRA was within 1.0–1.3. This value corresponds to a modest
eﬀect size.4 Therefore, it is unlikely that heterogeneity in the
genes among studies changed the main conclusion of this study.
Table 5. Details of covariates considered in each included study
First author Year Covariates
Oian18 2015 age, gender, BMI
Talmud17 2015 age, gender, BMI, BP, HDL, TG
Chen21 2014 age, gender, dialect, global ancestry
Langenberg20 2014 age, gender, BMI
Villegas19 2014 age, gender, BMI
Anand26 2013 age, gender, BMI, WC, FHDM, smoking, PA, Apo-A, Apo-B, HT
Imamura25 2013 age, gender, BMI
Kalnina27 2013 age, gender, BMI
Peters28 2013 age, gender, BMI, adiponectine
Ramya24 2013 age, gender, BMI
Robiou-du-Pont23 2013 age, gender, BMI
Tam22 2013 age, gender, BMI
Cauchi29 2012 age, gender
Cooke30 2012 age, gender
Gamboa-Meiendez31 2012 age, gender, BMI
Iwata32 2012 age, gender, BMI
Long33 2012 age, gender, BMI
Vassy34 2012 age, gender, race, FH of DM, BMI, FPG, HDL, TG, PA, smoking,
alcohol
Vassy35 2012 age, gender, race, FH, BMI, MAP, FPG, HDL, TG
Villegas36 2012 age, gender, BMI
Yamakawa-
Kobayashi37
2012 age, gender, BMI
Li38 2011 age, gender, BMI
Martinez-Gomez39 2011 age, gender
Rees40 2011 age, gender, BMI
Tabara41 2011 age, gender, BMI
Uusitupa42 2011 age, gender, BMI, BMI change, FH, intervention, FPG, 2hPG,
FPG change, 2hPG change, insulin, insulin change, 2h-insulin,
2h-insulin change
Fontaine-Bisson43 2010 age, gender
Qi44 2010 age, gender, BMI
Rotger45 2010 age, gender, BMI, treatment for HIV, CD4+, HDL, TG
Wang46 2010 ## FINDRISC score, TG, HDL, ALT, adiponectine
Waters47 2010 age, gender, BMI
Xu48 2010 age, gender, BMI, FH of DM, smoking, alcohol
Cornelis49 2009 age, gender, BMI, FH of DM, smoking, alcohol, PA
Hu50 2009 age, gender, BMI
Lin51 2009 age, BMI, FH of DM, TG=HDL, PA
Miyake52 2009 age, gender, BMI
Nordman53 2009 age, (gender), BMI, SBP, DBP
Rong54 2009 age, gender, BMI
Schulze55 2009 DRS scorea, HDL, TG, ALT
Cauchi56 2008 age, gender, BMI
Lyssenko57 2008 age, gender
Meigs58 2008 age, gender
Vaxillaire59 2008 age, gender, BMI
Scott60 2006 age, gender, birth province
Hansen61 2005 age, gender
Zacharova62 2005 age, (gender), BW, BW change, smoking, country
ALT, alanine aminotransferase; BMI, body mass index; CD4, cluster of
diﬀerentiation 4; DBP, diastolic blood pressure; HDL, high-density
lipoprotein cholesterol; FH of DM, family history of diabetes mellitus;
FPG, fasting plasma glucose; HIV, human immunodeﬁciency virus; MAP,
mean arterial blood pressure; SBP, systolic blood pressure; TG, triglycerides;
PA, physical activity.
aIncluding age, BMI, waist circumferences, PA, vegetable intake, past
history of hyperglycemia, and taking anti-hypertensive agents ### including
age, waist circumferences, height, hypertension, PA, smoking, meat intake,
intake of whole-grain bread, coﬀee, and alcohol.
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Table 6. Details of genes used in each included study that are associated with type 2 diabetes mellitus
First author Year
Number of
SNPs
Oian18 2015 9 CDKAL1, CDKN2A=2B, CENTD2, FTO, HHEX (2 SNPs), KCNQ1, SLC30A8, VEGFA
Talmud17 2015 65 ADAMTS9, ADCY5, ANK1, ANKRD55, AP3S2, BCAR1, BCL11A, C2CD4A, CCND2, CDC123=CAMK1D, CDKAL1, CDKN2A=B, CENTD2, CILP2,
DGKB, DUSP8, FTO, GCC1, GCK, GCKR, GIPR, GLIS3, GRB14, HHEX=IDE, HMG20A, HMGA2, HNF1A, HNF1B, HNF4A, IGF2BP2, IRS1, JAZF1,
KCNJ11, KCNK16, KCNQ1, KLF14, KLHDC5, MAEA, MC4R, MTNR1B, NOTCH2, PEPD, PPARG, PRC1, PROX1, PSMD6, PTPRD, RBMS1, SLC30A8,
SPRY2, SRR, ST64GAL1, TCF7L2, THADA, TLE1, TLE4, TP53INP1, TSPAN8=LGR5, UBE2E2, VPS26A, WFS1, ZBED3, ZFAND3, ZFAND6, ZMIZ1
Chen21 2014 19 ADAMTS9-MAGI1, ANK1, BCL11A-EIF3FP3, C6orf57, CDC123-CAMK1D, CDKAL1, CDKN2A=2B (2 SNPs), FTO, HHEX-EPOC6, HNF4A, IGF2BP2
(2 SNPs), IRS1-KIAA1486, KLF14-FLJ43663, PTPRD, THADA, TSPAN8-LGR5, VPS26A
Langenberg20 2014 49 ADAMTS9, ADCY5, ANK1, ANKRD55, BCAR1, BCL11A, CCND2, CDC123-CAMK1D, CDKAL1, CDKN2A=2B, CENTD2, CILP2, DUSP9, DGKB, FTO,
GCK, GCKR, GIPR, GRB14, HHEX-IDE, HMG20A, HMGA2, HNF1A, HNF1B, IGF2BP2, IRS1, KCNJ11, KCNQ1, KLF14, KLHDC5, MC4R, MTNR1B,
NOTCH2, PPARG, PRC1, PROX1, SLC30A8, SPRY2, TCF7L2, THADA, TLE1, TLE4, TP53INP1, TSPAN8-LGR5, UBE2E2, WFS1, ZBED3, ZFAND6,
ZMIZ1
Imamura25 2014 10 ANK1, C2CD4A=B, CDKAL1, CDKN2A=B, DUSP9, IGF2BP2, KCNQ1, MAEA, TCF7L2, UBE2E2
Villegas19 2014 15 ADAMTS9, CDC123-CAMK1D, CDKAL1, CDKN2A=2B, FTO, HHEX-IDE, IGF2BP2, JAZF1, KCNQ1, NOTCH2, PPARG, SLC30A8, TCF7L2, THADA,
TSPAN8-LGR5
Anand26 2013 16 CDKAL1, CDKN2A=2B, FTO, GATAD2A, GCKR, HHEX-IDE, HNF1B, IGF2BP2, IRS1, KCNJ11, KCNQ1, MTNR1B, PPARG, SLC30A8, TCF7L2, WFS1
Kalnina27 2013 2 FTO, TMEM18
Peters28 2013 3 ADIPOQ (3 SNPs)
Ramya24 2013 5 ADIPOQ (5 SNPs)
Robiou-du-Pont23 2013 24 AIF1, BDNF (2 SNPs), CTNNBL1, ETV5, FAIM2, FTO (2 SNPs), GNPDA2, KCTD15, MAF, MC4R, MTCH2, NEGR1, NPC1, PCSK1 (2 SNPs), PRL,
PTER, SDCCAG8, SEC16B, SH2B1, TMEM18, TNKS
Tam22 2013 14 ADAMTS9, CDKAL1, CDKN2A=2B, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, NOTCH2, SLC30A8, TCF7L2, TSPAN8-LGR5, WFS1
Cauchi29 2012 13 ADAMTS9, BCL11A, CDKAL1, CDKN2A=2B, FTO, GCK, HNF1A, IGF2BP2, KCNQ1, MC4R, TCF7L2, TP53INP1, WFS1
Cooke30 2012 17 ADAMTS9, CDKAL1, CDKN2A=2B, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, NOTCH2, PPARG, SLC30A8, TCF7L2, THADA,
TSPAN8-LGR5, WFS1
Gamboa-Meiendez31 2012 21 ADAMTS9, ARHGEF11, CDC123-CAMK1D, CDKAL1, CDKN2A=2B, FTO, HHEX (2 SNPs), IGF2BP2, JAZF1, KCNJ11, KCNQ1, NXPH1, NOTCH2,
PPARG, RALGPS2, RORA, SLC30A8, TCF7L2, TSPAN8-LGR5, UBQLNL
Iwata32 2012 14 CDKAL1, CDKN2B, GCKR, HHEX, IGF2BP2, IRS1, KCNJ11, KCNQ1, PPARG, PRC1, PROX1, SLC30A8, TCF7L2, UBE2E2
Long33 2012 29 ADAMTS9, BCL11A, C2CD4A=B, CDKAL1 (2 SNPs), CDKN2A=2B, CHCHD9, FTO, HHEX, HHEX-IDE, HMGA2, HNF1A, IGF2BP2 (2 SNPs), JAZF1,
KCNQ1 (3 SNPs), KLF14, NOTCH2-ADAM30, RBMS1-ITGB6, SRR, TCF7L2, THADA, TSPAN8-LGR5, WFS1 (2 SNPs), ZBED3, ZFAND6
Vassy34 2012 38 ADAMTS9, ADCY5, BCL11A, CDC123-CAMK1D, CDKAL1, CDKN2A=2B, CENTD2, DCD, DGKB-TMEM195, FTO, GCK, GCKR, HCCA2, HHEX,
HMGA2, HNF1A, HNF1B, IGF2BP2, IRS1, JAZF1, KCNJ11, KCNQ1 (2 SNPs), KLF14, MTNR1B, NOTCH2, PPARG, PRC1, PROX1, RBMS1-ITGB6,
SLC30A8, TCF7L2, THADA, TLE4, TP53INP1, TSPAN8-LGR5, VEGFA, WFS1
Vassy35 2012 38 ADAMTS9, ADCY5, BCL11A, CDC123-CAMK1D, CDKAL1, CDKN2A=2B, CENTD2, DCD, DGKB-TMEM195, FTO, GCK, GCKR, HCCA2, HHEX,
HMGA2, HNF1A, HNF1B, IGF2BP2, IRS1, JAZF1, KCNJ11, KCNQ1 (2 SNPs), KLF14, MTNR1B, NOTCH2, PPARG, PRC1, PROX1, RBMS1-ITGB6,
SLC30A8, TCF7L2, THADA, TLE4, TP53INP1, TSPAN8-LGR5, VEGFA, WFS1
Villegas36 2012 14 CDC123-CAMK1D, CDKAL1 (2 SNPs), CDKN2A=2B, HHEX-IDE (2 SNPs), HNF1B, IGF2BP2, KCNJ11, KCNK15, KCNQ1, SLC30A8, SPRY2,
TP53INP1
Yamakawa-Kobayashi37 2012 17 ADAMTS9, CDC123, CDC24A, CDKAL1, CDKN2A=2B, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, PPARG, SLC30A8, TCF7L2,
TSPAN8, UBE2E2
Li38 2011 12 BDNF, ETV5, FAIM2, FTO, GNPDA2, KCTD15, MC4R, MTCH2, NEGR1, SEC16B, SH2Bi, TMEM18
+Martinez-Gomez39 2011 5 CaPN10, IRS1, PPARG, TCF7L2 (2 SNPs)
Rees40 2011 28 ADAMTS9, BCL11A, CDC123-CAMK1D, CDKAL1, CDKN2A=2B, CENTD2, CHCHD9, DUSP9, FTO, HHEX-IDE, HNF1A, IGF2BP2, IRS1, JAZF1,
KCNJ11, KCNQ1 (2 SNPs), KLF14, NOTCH2, PPARG, PRC1, SLC30A8, TCF7L2, THADA, TP53INP1, TSPAN8-LGR5, WFS1, ZBED3
Tabara41 2011 10 CDKAL1, CDKN2A=2B, GCKR, HHEX, IGF2BP2, KCNJ11, KCNQ1, PPARG, SLC30A8, TCF7L2
Uusitupa42 2011 19 ADAMTS9, CDC123, CDKAL1, CDKN2B, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, MTNR1B, NOTCH2, PPARG, SLC30A8, TCF7L2,
THADA, TSPAN8, WFS1
Fontaine-Bisson43 2010 17 CDC123-CAMK1D, CDKN2A=2B, DCD, EXT2, HHEX (2 SNPs), HNF1B, KCNJ11, LOC387761, NOTCH2, PPARG, SLC30A8, TCF7L2, THADA,
TSPAN8-LGR5, VEGFA, WFS1
Qi44 2010 17 ADAMTS9, CDC123-CAMK1D, CDKAL1, CDKN2A=2B, GCKR, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, MTNR1B, PPARG, SLC30A8,
TCF7L2, TSPAN-LGR5, WFS1
Rotger45 2010 4 FTO, KCNJ11, TCF7L2, TSPAN-LGR5
Wang46 2010 20 ADAMTS9, CDC123, CDKAL1, CDKN2A=2B, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, LOC387761, MTNR1B, NOTCH2, PPARG,
SLC30A8, TCF7L2, THADA, TSPAN8, WFS1
Waters47 2010 19 ADAMTS9, CDC123, CDKAL1, CDKN2A=2B, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, (2 SNPs), NOTCH2, PPARG, SLC30A8, TCF7L2,
THADA, TSPAN8, WFS1
Xu48 2010 4 CDKAL1, CDKN2A=2B, KCNQ1, SLC30A8
Cornelis49 2009 10 CDKAL 1, CDKN2A=2B (2 SNPs), HHEX, IGF2BP2, KCNJ11, PPARG, SLC30A8, TCF7L2, WFS1
Hu50 2009 11 CDKAL1, CDKN2A=2B, FTO, HNF1B, IDE-KIF11-HHEX, IGF2BP2, KCNJ11, KCNQ1, PPARG, SLC30A8, WFS1
Lin51 2009 15 ADAMTS9, CDC123-CAMK1D, CDKAL1, CDKN2A=2B, FTO, HHEX-IDE, IGF2BP2, JAZF1, KCNJ11, NOTCH2, PPARG, TCF7L2, THADA, TSPAN-
LGR5, WFS1
Miyake52 2009 11 CDKAL1, CDKN2B, GCKR, HHEX, HNF1B, IGF2BP2, KCNJ11, KCNQ1, PPARG, SLC30A8, TCF7L2
Nordman53 2009 3 HHEX, IDE, TCF7L2
Rong54 2009 7 CDKAL1, CDKN2B, FTO, HHEX, IGF2BP2, SLC30A8, TCF7L2
Schulze55 2009 20 ADAMTS9, BCL11A, CDC123-CAMK1D, CDKAL1, CDKN2A=2B, DCD, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, NOTCH2, PPARG,
SLC30A8, TCF7L2, THADA, TSPAN8-LGR5, VEGFA, WFS1
Cauchi56 2008 15 CAMTA1, CDKAL1, CDKN2A=2B, CXCR4, EXT2, HHEX, IGF2BP2, KCTD12, LDLR, LOC387761,
Lyssenko57 2008 11 CDKAL1, FTO, HHEX, IGF2BP2, JAZF1, KCNJ11, NOTCH2, PPARG, SLC30A8, TCF7L2WFS1
Meigs58 2008 18 ADAMTS9, BCL11A, CDC123-CAMK1D, CDKAL1, CDKN2A=2B, DCD, HHEX, IGF2BP2, INS, JAZF1, KCNJ11, NOTCH2, PPARG, SLC30A8,
TCF7L2, THADA, TSPAN8-LGR5, VEGFA
Vaxillaire59 2008 3 GCK, IL6, TCF7L2
Scott60 2006 3 KCNJ11, PPARG, TCF7L2
Hansen61 2005 2 KCNJ11, PPARG
+Zacharova62 2005 2 ADIPOQ (2 SNPs)
SNP, single nucleotide polymorphism.
+The 2 studies used a dominant model.
The other studies used an additive model.
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Nevertheless, the heterogeneity in the magnitude of T2DM risk
due to the heterogeneity among the used genes urges us interpret
the results with caution.
The current stratiﬁed meta-analysis of cross-sectional studies
indicated that a larger magnitude of T2DM risk in relation to
cumulative RAs was observed in studies with a proportion of
men 50% or greater compared with women-dominant studies,
suggesting that the magnitude of the genetic association with
T2DM was larger in men than in women. Although evidence
for gender-related diﬀerences in genetic associations has been
insuﬃcient,67 some major longitudinal studies suggested that the
environmental contribution to T2DM risk diﬀered by gender.
For example, regarding moderate physical activity, which has
been established to reduce T2DM risk,68 the MONICA=KORA
Augsburg Cohort study suggested that leisure time physical
activity was eﬀective in preventing T2DM, especially in
women.69 In the intensive lifestyle modiﬁcation group in the
Diabetes Prevention Program, the eﬀect in preventing incident
T2DM did not diﬀer by sex, although men lost signiﬁcantly more
body weight and increased physical activity more than did
women.70 The relative contribution of genetic risk to incident
T2DM could be smaller in women than in men. Further studies
would need to analyze the T2DM risk in relation to genetic
risk by gender to clarify the gender diﬀerence in the relative
contribution of genetic proﬁles. Of note, this suggestion was
Table 7. Rank of the number of genes that were used to examine
the association with the prevalence or incidence of type
2 diabetes mellitus
Number of studies Genes
34 CDKAL1, TCF7L2
33 CDKN, HHEX
31 IGFBP2
29 SLC30A8
28 KCNJ11
27 PPARγ
25 FTO, KCNQ1
21 TCF1B, TSPAN8
20 ADAMST9, WFS1
19 JAZF1
18 NOTCH2
17 CDC123
16 THADA
10 BCL11A
9 GCKR, IRS1
8 HNF1A
7 KLF14, MTNR1B, TP53INP1
6 CENTD2, GCK, PRC1, VEGFA
5 DCD, HMGA2, MC4R, PROX1, UBE2E2
4 ADCY5, ANK1, DGKB, TLE4, RBMS1-ITGB6, ZBED3
3 ADIPOQ, C2CD4A=B, DUSP9, LOC387761, SPRY2, ZFAND6
2 ANKRD55, BCAR1, BDNF, CCND2, CHCHD9, CILP2, ETV5, EXT2, FAIM2,
GIPR, GNPDA2, GRB14, HCCA2, HMG20A, KCTD15, KLHDC5, MAEA,
MTCH2, NEGR1, PTPRD, SEC16B, SH2B1, SRR, TLE1, VPS26A, ZMIZ1
1 AIF1, AMTA1, AP3S2, ARHGEF11, C6orf57, CaPN10, CDC24A, CTNNBL1,
CXCR4, DUSP8, EXT2, GATAD2A, GCC1, GLIS3, HNF4A, IL6, INS, KCNK15,
KCNK16, KCTD12, IDE, LDLR, LOC646279, MAF, MMP26, NXPH1, NGN3,
NPC1, PCSK1, PEPD, PRC1, PRL, PROX1, PSMD6, PTER, RALGPS2, RORA,
SDCCAG8, ST64GAL1, TMEM18, TNKS, UBQLNL, ZFAND3
Figure 2. Forest plot of odds ratio (OR) with 95% conﬁdence interval (CI) for risk of type 2 diabetes mellitus with 95% CI for 1
increment in risk alleles carried in cross-sectional studies. The OR in each study and the overall OR are indicated by
squares and a diamond, respectively. Horizontal lines indicate the range of the 95% CI. The area of each square is
proportional to the study weight expressed as the inverse of the square of standard error based on a random-eﬀects
model.
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Table 8. Stratiﬁed meta-analysis of eligible cross-sectional studies by several study items related to study characteristics for the pooled
odds ratio (OR) for type 2 diabetes mellitus (DM) per 1 increase in risk alleles carried in relation to single nucleotide
polymorphism (SNP)
Item Number of data OR (95% CI) Q statistics I-squared
P value of
heterogeneity
Meta-regression $
Total 40 1.16 (1.13–1.19) 613.3 93.6% <0.001
Number of SNPs <10 12 1.25 (1.11–1.31) 37.8 70.9% <0.001
≥10 28 1.14 (1.11–1.17) 522.1 94.8% <0.001 0.002
Mean age <55 years 16 1.17 (1.11–1.22) 191.4 92.2% <0.001
≥55 years 24 1.16 (1.13–1.20) 395.5 94.2% <0.001 0.95
Proportion of men <50% 26 1.14 (1.11–1.17) 361.5 93.1% <0.001
≥50% 13 1.21 (1.16–1.26) 101.6 88.2% <0.001 0.04#
N=A 1 1.13 (1.05–1.22) — — — —
Country Western 24 1.13 (1.10–1.16) 307.0 92.5% <0.001
Non-Western 16 1.20 (1.16–1.25) 213.7 93.0% <0.001 0.01
Dominant ethnic group Asian 16 1.20 (1.16–1.25) 233.4 93.6% <0.001
Non-Asian 24 1.13 (1.10–1.16) 273.4 91.6% <0.001 0.01
Mean BMI+ <27 kg=m2 22 1.19 (1.15–1.24) 448.4 95.3% <0.001
≥27 kg=m2 18 1.11 (1.09–1.14) 88.3 80.7% <0.001 0.03
Adjustment for BMI Yes 31 1.16 (1.13–1.20) 535.5 94.4% <0.001
No 9 1.15 (1.10–1.21) 66 87.9% <0.001 0.82
Using OGTT to diagnose DM Yes 14 1.19 (1.14–1.25) 205.1 93.7% <0.001
No 26 1.15 (1.11–1.18) 389.0 93.6% <0.001 0.17
Excluding IGT from non-cases Yes 7 1.28 (1.22–1.34) 15.4 31.0% 0.009
No 33 1.14 (1.12–1.17) 508.5 93.5% <0.001 0.002
Excluding IFG from non-cases Yes 13 1.18 (1.13–1.23) 189.6 93.7% <0.001
No 27 1.15 (1.12–1.19) 406.5 93.6% <0.001 0.42
BMI, body mass index; CI, conﬁdence interval; DM, diabetes mellitus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; OGTT, oral glucose
tolerance test; OR, odds ratio; SNPs, single nucleotide polymorphisms.
Table 9. Univariate and multivariate meta-regression analyses of eligible cross-sectional studies for odds ratio for type 2 diabetes mellitus
(T2DM) for 1 increment in risk alleles carried in relation to diabetes-associated single nucleotide polymorphisms (SNPs) by
characteristics of study designa
Variable
Univariateb N = 40 Multivariate 1 N = 39c Multivariate 2 N = 39c
Coeﬃcientd SE P Coeﬃcient SE P Coeﬃcient SE P
No. SNPs ≥10 −0.094 0.029 0.002 −0.077 0.033 0.03 −0.084 0.033 0.02
Western country −0.062 0.025 0.02 −0.060 0.025 0.02 e
Asian ethnicity 0.065 0.025 0.01 e 0.081 0.031 0.02
Mean age ≥55 years −0.002 0.028 0.95 −0.003 0.021 0.90 −0.019 0.023 0.42
Women-dominantc −0.061 0.028 0.04 −0.065 0.022 0.005 −0.064 0.022 0.006
BMI ≥27 kg=m2 −0.057 0.025 0.03 −0.005 0.025 0.84 0.018 0.027 0.56
Adjustment for BMI 0.009 0.033 0.79 0.024 0.028 0.40 0.024 0.028 0.39
Using OGTT to diagnose DM 0.039 0.028 0.17 −0.004 0.026 0.88 −0.017 0.027 0.53
Excluding IGT from noncases 0.115 0.035 0.002 0.074 0.046 0.12 0.074 0.046 0.12
Excluding IFG from noncases 0.023 0.028 0.42 −0.019 0.023 0.42 −0.010 0.023 0.66
R-squared 64.4% 61.4%
F-test F(9,29) = 4.60 P < 0.001 F(9,29) = 4.70 P < 0.001
Abbreviations: Same as in Table 8.
aLogarithm of odds ratio for T2DM was a dependent variable, and each study characteristic was entered as an explanatory variable.
bFundamentally, results were consistent with the stratiﬁed analysis.
cN = 39 because one study54 in which the proportion of men was not available was excluded.
dPositive value of the coeﬃcient means that the OR is higher when the answer to each variable is “Yes” compared with a “No” answer. The same interpretation of
the results is applied to Table 10, Table 12, and Table 13.
eWestern country and Asian ethnicity was not entered simultaneously because of collinearlity.
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contradictory to the ﬁnding in one of the included studies in this
meta-analysis, which indicated that carrying RAs was associated
with T2DM in women but not in men.62 However, this study
focused on ADIPOQ among the established T2DM-susceptible
genes and limited the subjects to those who already had IGT at
cohort entry. ADIPOQ might play a role in the determination of
the severity of glucose tolerance, especially in women, although
the majority of SNPs used for T2DM screening was associated
with discrimination of glucose intolerance from normal glucose
tolerance.
Current sensitivity analyses indicated that there was a stronger
association between cumulative RAs and T2DM risk in study
populations with lower mean BMI. This ﬁnding was supported by
previous studies that stratiﬁed the analyses by BMI, although
these data could not be included in this meta-analysis because
characteristics other than BMI in each subgroup were not
presented.20,25 However, ethnicity or geographic region, rather
than obesity, might aﬀect the strength of the association between
cumulative RAs and T2DM risk, considering that the prevalence
of overweight and obesity in Asia is relatively low compared
with Western populations.71 To our knowledge, no studies have
investigated the diﬀerence in the magnitude of T2DM risk by
ethnicity using two or more SNPs, although a diﬀerence in the
attributable risk of a certain T2DM-susceptible SNP has been
suggested.72 Whether an included study was targeted on an
Asian-dominant ethnicity or whether it was conducted in Western
countries aﬀected the magnitude of T2DM risk for an increment
in the number of RAs carried in both univariate and multivariate
meta-regression analyses. However, modiﬁcation of the magni-
tude of T2DM risk by the mean BMI that was shown in univariate
analyses disappeared in the multivariate analyses. It could be
interpreted that the contribution of genes to T2DM risk could
Table 10. Univariate and multivariate meta-regression analyses
of eligible cross-sectional studies for odds ratio for type
2 diabetes mellitus (T2DM) for 1 increment in risk
alleles carried in relation to diabetes-associated single
nucleotide polymorphisms (SNPs) by whether or not
each of the top 10 of commonly used genes in this
meta-analysis was examineda
Genes
Univariate N = 40 Multivariate N = 40
coeﬃcient SE P coeﬃcient SE P
CDKAL1 −0.073 0.033 0.03 −0.061 0.069 0.38
TCF7L2 −0.016 0.031 0.60 0.015 0.035 0.65
CDKN −0.073 0.033 0.03 b
HHEX −0.067 0.029 0.03 −0.025 0.056 0.65
IGFBP2 −0.061 0.029 0.04 0.010 0.052 0.84
SLC30A8 −0.029 0.029 0.03 0.026 0.047 0.58
KCNJ11 −0.004 0.027 0.89 0.008 0.033 0.81
PPARγ −0.030 0.027 0.28 −0.025 0.037 0.51
FTO −0.101 0.021 <0.001 −0.087 0.027 0.003
KCNQ1 −0.037 0.028 0.20 0.011 0.041 0.08
R-squared 59.9%
F-test F(9,30) = 2.39 P = 0.04
SE, standard error.
aLogarithm of odds ratio for diabetes mellitus was a dependent variable, and
each study characteristic was entered as an explanatory variable.
bCDKN could not be entered simultaneously because of collinearlity.
Figure 3. Forest plot of odds ratio (OR) with 95% conﬁdence interval (CI) for risk of type 2 diabetes mellitus with 95% CI for 1
increment in risk alleles carried in longitudinal studies. The OR in each study and the overall OR are indicated in
squares and a diamond, respectively. Horizontal lines indicate the range of the 95% CI. The area of each square is
proportional to the study weight expressed as the inverse of the square of standard error based on a random-eﬀects
model.
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be aﬀected by ethnicity rather than physical background.
Unfortunately, when applied to the included studies in the
current meta-analysis, this hypothesis was directly elucidated by
only one study, which compared the magnitude of T2DM risk
between Asian and non-Asian ethnic groups.47 Further studies
are needed to conﬁrm the characteristics of individuals or
populations that are susceptible to genetic T2DM risk, including
determinations of whether the characteristic was the extent of
obesity or ethnicity.
The result of the current stratiﬁed meta-analyses might reﬂect
characteristics regarding metabolic traits of persons at high
genetic risk of T2DM: a higher OR was observed in studies that
excluded subjects without T2DM who had IGT compared with
studies that did not exclude subjects with IGT, but no diﬀerence
Table 11. Stratiﬁed meta-analysis of eligible longitudinal studies by several study items related to study characteristics for pooled odds
ratio (OR) of type 2 diabetes mellitus (DM) per 1 increment in risk alleles carried in relation to single nucleotide polymorphism
(SNP)
Item
Number of
data
OR (95% CI) Q statistics I-squared
P value of
heterogeneity
Meta-regressiond
Total 21 1.10 (1.08–1.13) 94.5 78.8% <0.001
Number of SNPs <10 4 1.34 (1.21–1.49) 4.6 35.2% 0.20
≥10 17 1.10 (1.07–1.12) 74.8 78.6% <0.001 0.005
Mean ageb <50 years 9 1.11 (1.06–1.14) 28.6 72.0% <0.001
≥50 years 11 1.11 (1.07–1.15) 60.2 83.4% <0.001 0.95
Proportion of men <50% 15 1.09 (1.06–1.12) 65.3 78.6% <0.001
≥50% 6 1.14 (1.09–1.20) 21.3 76.6% 0.00 0.19
Country Western 19 1.10 (1.08–1.13) 91.1 80.2% <0.001
Non-Western 2 1.16 (1.05–1.29) 2.1 51.3% 0.15 0.40
Dominant ethnic Group White 15 1.10 (1.08–1.13) 89.3 83.2% <0.001
Non-White 5 1.10 (1.06–1.13) 5.2 23.1% 0.27 0.94
Mean BMIa,b,c <25 kg=m2 7 1.12 (1.08–1.17) 15.6 61.5% 0.02
≥25 kg=m2 13 1.10 (1.07–1.13) 75.8 84.2% <0.001 0.5
Adjustment for BMI Yes 17 1.10 (1.08–1.13) 63.0 74.6% <0.001
No 4 1.10 (1.05–1.16) 18.5 83.8% <0.001 0.96
Using OGTT to diagnose DM Yes 12 1.11 (1.07–1.15) 41.5 73.5% <0.001
No 9 1.10 (1.06–1.13) 45.1 82.3% <0.001 0.80
BMI, body mass index; OGTT, oral glucose tolerance test; IGT, impaired glucose tolerance; N=A, not applicable.
aIndicates mean BMI of study population at recruitment.
bOne study17 did not present data on mean age or BMI.
cIndicates mean BMI at the beginning of follow-up.
dP value for diﬀerence in the magnitude of logarithm of odds ratio between strata was indicated.
Table 12. Univariate and multivariate meta-regression analysis of eligible longitudinal studies for odds ratio of type 2 diabetes mellitus for
1 increment in risk alleles in relation to diabetes-associated single nucleotide polymorphism (SNP)a according to characteristics
of study designa
Variable
Univariatec N = 21 Multivariate 1 N = 20b Multivariate 2 N = 20b
coeﬃcient SE P coeﬃcient SE P coeﬃcient SE P
Number of SNPs ≥10 (Yes=No) −0.206 0.066 0.005 −0.182 0.083 0.049 −0.186 0.082 0.04
Western country (Yes=No) −0.067 0.078 0.40 −0.035 0.091 0.7 d
White-dominant (Yes=No) −0.003 0.039 0.94 d 0.002 0.04 0.97
Mean age ≥50 years (Yes=No)b 0.002 0.034 0.95 0.01 0.04 0.82 0.017 0.037 0.67
Women-dominant −0.045 0.033 0.19 −0.052 0.042 0.24 −0.049 0.042 0.27
BMI ≥25 kg=m2 (Yes=No) −0.025 0.036 0.50 0.01 0.048 0.84 0.000 0.043 1.00
Adjustment for BMI 0.002 0.038 0.96 −0.011 0.04 0.79 −0.007 0.042 0.88
Using OGTT to diagnose DM 0.008 0.032 0.80 −0.006 0.035 0.87 −0.004 0.035 0.91
R-squared 49.1% 47.5%
F-test F(7,12) = 1.39 P = 0.29 F(7,12) = 1.37 P = 0.30
BMI, body mass index; DM, diabetes mellitus; OGTT, oral glucose tolerance test; SE, standard error.
aLogarithm of odds ratio for diabetes mellitus was a dependent variable, and each study characteristic was entered as an explanatory variable.
bN = 20 because one study17 did not present data on mean age or BMI.
cFundamentally, the results were consistent with the stratiﬁed analysis.
dWestern country and Asian ethnicity was not entered simultaneously because of collinearlity.
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in ORs was observed according to whether or not subjects with
IFG were excluded, which meant that inclusion of subjects with
IGT in the non-case group weakened the association between
cumulative RA and T2DM risk. A previous study reported that
the genetic risk score was reported to be cross-sectionally
associated with the risk of having IGT but not IFG using nine
genes (FTO, HHEX, KCNJ11, KCNQ1, MTNR1B, PPARG,
SLC30A8, TCF7L2, WFS1), which were established to be major
loci associated with the risk of T2DM.73 When applying this
ﬁnding to this meta-analysis, seven of these nine genes were
ranked in the top 10 genes that frequently appeared in the
included studies in this meta-analysis. Major T2DM-associated
genes that were discovered in the current GWAS might have a
stronger association with glucose intolerance than T2DM itself.
Considering that T2DM is a partly a result of progression of
glucose intolerance, incident T2DM could be prevented by non-
genetic factors, although mild glucose tolerance was inevitably
regulated by genes. This suggestion was supported by evidence
for the beneﬁt of lifestyle interventions in reducing the risk of
progression from IGT to T2DM.74
Several limitations should be addressed. First, this meta-
analysis had to assume the log-linearity between the number of
RAs carried and the observed T2DM risk. Second, this meta-
analysis assumed that each SNP within one study would equally
contribute to the risk of T2DM, although the OR for each SNP
varied. However, it was reported that the diﬀerence in the
discriminative power between using an unweighted and weighted
genetic risk score was not signiﬁcant43 or was modest.51 Third,
as previously mentioned, the genes that were used in the
examination of the association with prevalence and incidence of
T2DM were too heterogeneous to analyze by the combination of
the used genes. Nevertheless, the genes used for genetic risk
should be the same across the studies. Fourth, this meta-analysis
also did not consider heterogeneity in covariates for which each
study adjusted T2DM risk. To minimize this heterogeneity,
analyses were limited to the ORs that were adjusted for at least
two of three covariates: age, gender, and BMI. In addition,
sensitivity analyses conﬁrmed that the magnitude of T2DM risk
was not inﬂuenced by whether these ORs were adjusted for BMI.
Therefore, the current meta-analysis could conﬁrm that the
genetic T2DM risk was independent of age, gender, and obesity.
Although these are well known to be major classic risk factors for
T2DM, it needs to be emphasized that other residual confounders
could not be ruled out.
Conclusions
The current meta-analysis indicated that carrying one RA in
T2DM-associated SNPs was associated with a modest risk of
prevalent or incident T2DM as far as the SNPs discovered in
GWAS were concerned, although the heterogeneity in the genes
examined among studies indicates that we should interpret the
results with caution.
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